https://www.selleckchem.com/pr....oducts/phosphoramido
025, HR 2.39, 95% CI 1.12-5.11; P=0.017, HR 3.14, 95% CI 1.22-8.06; P=0.033, HR 0.63, 95% CI 0.41-0.96; P0.001, HR 11.88, 95% CI 5.79-24.38; P=0.002, HR 0.98, 95% CI 0.96-0.99, respectively). In Korean women with NSCLC, smoking status, not receiving active anticancer treatment, EGFR mutation status, lung cancer stage, and pulmonary function were significantly associated with mortality. In Korean women with NSCLC, smoking status, not receiving active anticancer treatment, EGFR mutation status, lung cancer stage,
Like
Comment
Share
